Table 1 Baseline characteristics
Overall | ILD | Asthma | COPD | Lung cancer | p-value | |
|---|---|---|---|---|---|---|
Subjects (n) | 322 | 161 | 65 | 50 | 46 | |
Females (n) | 154 (47.8) | 60 (37.3) | 45 (69.2) | 23 (46.0) | 26 (56.5) | < 0.01 |
Age (years) | 68 [58, 75] | 71 [62, 76] | 56 [42, 67] | 66 [61, 74] | 69 [63, 75] | < 0.01 |
Smoking amount ~ (py) | 32.6 (31.5)* | 25.8 (23.3) | 16.3 (15.9) | 49.6 (38.7) | 41.9 (38.4) | < 0.01 |
Smoking status | < 0.01 | |||||
Never | 96 (30.7) | 48 (30.4) | 37 (56.9) | 0 (0.0) | 13 (28.3) | |
Former | 193 (59.9) | 110 (68.3) | 23 (35.4) | 31 (66.0) | 27 (58.7) | |
Current | 30 (9.3) | 2 (1.2) | 5 (7.7) | 17 (34.0) | 6 (13.0) | |
FVC (%pred) | 84.7 (20.6)** | 80.7 (20.8) | 93.2 (16.7) | 84.2 (20.4) | 94.2 (22.1) | < 0.01 |
FEV1 (%pred) | 77.3 (22.4)** | 81.7 (19.0) | 81.6 (21.0) | 54.5 (21.3) | 85.3 (21.1) | < 0.01 |
DLCOc (%pred) | 51.0 (16.2)# | |||||
Diagnosis or Stage (n) | IPF 61 (37.9) HP 27 (16.8) CTD-ILD 27 (16.8) iNSIP 11 (6.8) CPFE 7 (4.3) COP 6 (3.7) Other ILD 22 (13.7) | GOLD I 16 (32.0) GOLD II 20 (40.0) GOLD III 7 (14.0) GOLD IV 7 (14.0) | SCLC 4 (8.7) NSCLC 42 (91.3) –––––––––––– Stage I 2 (4.3) Stage II 0 (0.0) Stage III 5 (10.9) Stage IV 39 (84.8) | |||
Eosinophil count (109/L) | 0.2 [0.1, 0.4]** | |||||
Use of immunosuppressants (n) | 55 (34.2)^ | 7 (10.8) | 4 (8.0) | 9 (19.6) | ||
Use of other disease-specific medication (n) | Antifibrotic 44 (27.3) | Biological 14 (21.5) ICS 59 (90.8) | ICS 30 (50.0) | Targeted 30 (65.2) CT and/or IT 10 (21.7) |